ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.)

ADVMのニュース

   Is Adverum Biotechnologies (ADVM) Outperforming Other Medical Stocks This Year?  2020/05/07 15:30:16 Zacks Investment Research
Is (ADVM) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom to Join S&P 500  2020/05/07 11:41:00 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) (reacted to its first-quarter results and clinical pipeline update) AstraZeneca plc (NYSE: AZN ) ( announced FDA approval for label expansion for its Farxiga) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp (NASDAQ: CTSO ) (reacted to its strong first-quarter results) DexCom, Inc. (NASDAQ: DXCM ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-quarter results) Horizon Therapeutics PLC (NASDAQ: HZNP ) (reacted to first-quarter results) I mara Inc (NASDAQ: IMRA ) Immunomedics, Inc. (NASDAQ: IMMU ) Immunovant Inc (NASDAQ: IMVT ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MacroGenics Inc (NASDAQ: MGNX ) (reacted to its first-quarter results and sell-side reactions to the results) Masimo Corporation (NASDAQ: MASI ) Meridian Bioscience, Inc.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Here's Why Momentum Investors Will Love Adverum Biotechnologies (ADVM)  2020/04/28 16:00:11 Zacks Investment Research
Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Why Earnings Season Could Be Great for Adverum (ADVM)  2020/03/11 13:46:00 Zacks Investment Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Why Earnings Season Could Be Great for Adverum (ADVM)  2020/03/11 13:46:00 Zacks Investment Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline  2020/02/26 17:30:38 Zacks Investment Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm  2020/02/25 17:26:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADVM #ADVM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data  2020/02/10 19:01:08 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-related macular degeneration, or AMD. Efficacy, Safety Established Adverum said data from six patients in cohort two were treated with a single intravitreal injection of a threefold lower dose of ADVM-022 compared to the first cohort showed that the gene therapy demonstrated robust efficacy and evidence of a dose response. Four of the six patients in the second cohort remained rescue injection-free at 24 weeks at the low dose, while all six patients in the first cohort remained rescue injection-free at a median follow-up of 50 weeks, the company said. And for these patients, vision was generally maintained … Full story available on Benzinga.com
   Why Earnings Season Could Be Great for Adverum (ADVM)  2020/03/11 13:46:00 Zacks Investment Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline  2020/02/26 17:30:38 Zacks Investment Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm  2020/02/25 17:26:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADVM #ADVM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data  2020/02/10 19:01:08 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-related macular degeneration, or AMD. Efficacy, Safety Established Adverum said data from six patients in cohort two were treated with a single intravitreal injection of a threefold lower dose of ADVM-022 compared to the first cohort showed that the gene therapy demonstrated robust efficacy and evidence of a dose response. Four of the six patients in the second cohort remained rescue injection-free at 24 weeks at the low dose, while all six patients in the first cohort remained rescue injection-free at a median follow-up of 50 weeks, the company said. And for these patients, vision was generally maintained … Full story available on Benzinga.com

calendar